TILADE
LOE ApproachingNDAINHALATIONSOLUTION
Approved
Oct 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TILADE is an inhaled small-molecule solution approved in 1997 for respiratory indications. The drug mechanism of action and specific indications are not publicly detailed in available data. It represents a mature product in Sanofi's respiratory portfolio with inhalation delivery.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30%), indicating a consolidating team focused on lifecycle extension and portfolio optimization.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Roles on TILADE focus on defending market share and maximizing lifecycle value as generic entry approaches. Career opportunities are limited in scope but valuable for developing expertise in LOE management, payer negotiations, and niche market positioning.
Brand ManagerMedical Science Liaison
Worked on TILADE at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.